Oxygen Biotherapeutics, Inc (NASDAQ:OXBT)’s shares dipped by 8.57% on Wednesday

Boston, MA, 11/14/2013 (nysepost) – In Wednesday’s trading session, Oxygen Biotherapeutics, Inc (NASDAQ:OXBT) dropped by 8.57%. The shares opened at a price of $6.81, which touched the intraday high of $6.90 and headed to a close of $6.40. Around 1.60 million exchanged hands over the trading day and an average volume of 5.34 million shares were traded over a 30 day period. The 52-week low of Oxygen Biotherapeutics, Inc (NASDAQ:OXBT) shares is $1.19 and its 52-week high is $20.00. The company has a market capitalization of $32.33 billion.                                        

About the company

Oxygen Biotherapeutics, Inc (NASDAQ:OXBT) is involved in developing bio-technology products that have a primary focus on oxygen-delivery to tissue. As of 30 April 30, it is developing Oxycyte. This is a systemic-perfluorcarbon product. It has developed a huge family of perfluorocarbon-based-oxygen carriers that are to be used in personal care, topical-wound healing as well as other topical indications. In addition to this, Oxygen Biotherapeutics, Inc (NASDAQ:OXBT) has under its development Vitavent. This  an oxygen-exchange fluid that is used for facilitating  treatment of various lung conditions & it has out licensed  the rights to its biosensor-implant product that utilizes an enzyme-process for measurement of glucose level in the subcutaneous fluid.

Oxycyte product

Oxygen Biotherapeutics, Inc (NASDAQ:OXBT)’s Oxycyte oxygen carrier product is a PFC- based oil-in water emulsion. This product is given to the patient intravenously. The physical-properties of PFC allow its product to gather the oxygen from lungs and transport this oxygen through the entire body releasing it as it moves along. Over a period of few days Oxycyte slowly evaporates inside the lungs from where it is later exhaled. Oxycyte is provided as this sterile emulsion that ready for intravenous-administration.

Dermacyte product

Oxygen Biotherapeutics, Inc (NASDAQ:OXBT)’s Dermacyte line of topical-cosmetic products employ its PFC technology & other known cosmetic -ingredients to promote appearance of skin-health and other desirable-cosmetic benefits.

About the Author

Guy Mezger, HHP, CMNAGuy Mezger is the managing partner and holistic health practitioner at Optimal Health Specialists. He has his degree in holistic health and is a certified holistic health practitioner and is currently working on his PhD in natural health sciences at the University of Natural Medicine. In addition to these studies, he has been working with renowned physicians such as Dr. John Fitzgerald for Naturopathic blood analysis and supplementation, Dr. Peter Goldman for holistic physical therapy and Dr. Kevin Shelton for bio-identical hormone balancing.Guy has been working in the fields of health, fitness, physical performance and marital arts for 25 years. He has worked with children, adults, athletes (both professional and amateur), civil and federal law enforcement agencies along with various Special Forces units of the United States military.Before taking on the role of a full time health practitioner and instructor, Guy was a professional combat athlete winning 5 world titles in 4 separate full contact sports. He is most recognized for his accomplishments in Mixed Martial Arts winning both the UFC and King of Pancrase titles.